Revolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings Results

Revolution Medicines (NASDAQ:RVMD) posted its earnings results on Wednesday. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46), FiscalAI reports. During the same quarter in the prior year, the company posted ($1.13) earnings per share.

Here are the key takeaways from Revolution Medicines’ conference call:

• Daraxonrasib delivered an unprecedented benefit in RASolute 302, meeting primary and key secondary endpoints with a 60% reduction in risk of death versus chemotherapy and a median overall survival exceeding one year; the company intends to submit an NDA, has FDA approval to start an expanded access program, and will present detailed data in an ASCO plenary.
• The company significantly strengthened its balance sheet with an historic $2 billion dual-tranche capital raise and reported $1.9 billion in cash at quarter end (plus $2.1 billion net proceeds in April), positioning it to advance four clinical-stage RAS(ON) inhibitors and next-generation programs.
• Operating costs rose sharply—Q1 stock-based compensation was $87.3M (vs. $25.1M a year ago) after a program modification—and RevMed raised full-year stock-based comp guidance by ~$80M, now expecting GAAP operating expenses of $1.7 billion to $1.8 billion, contributing to a Q1 net loss of $453.8M.
• The development plan is broad: multiple registrational trials are underway or planned across pancreatic, NSCLC, and colorectal cancer (including expansions of RASolve 301 and initiation of RASolute 303/304/305/308/309), and early-stage programs like RM-055 (catalytic RAS(ON) inhibitor) and RMC-5127 are progressing toward first-in-human studies.

Revolution Medicines Stock Performance

Shares of RVMD stock traded down $0.39 during trading hours on Friday, reaching $142.12. 863,135 shares of the company’s stock were exchanged, compared to its average volume of 3,482,924. Revolution Medicines has a fifty-two week low of $34.00 and a fifty-two week high of $155.70. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $30.21 billion, a P/E ratio of -20.05 and a beta of 1.41. The business has a fifty day moving average price of $113.41 and a 200-day moving average price of $94.43.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RVMD. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Truist Financial raised Revolution Medicines to a “strong-buy” rating in a research report on Monday, April 27th. UBS Group started coverage on Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating on the stock. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Finally, Wedbush upped their price objective on shares of Revolution Medicines to $165.00 and gave the stock an “outperform” rating in a report on Thursday. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $103.88.

Insider Buying and Selling at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $427,962.96. Following the transaction, the insider directly owned 295,398 shares in the company, valued at $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark A. Goldsmith sold 120,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider directly owned 276,698 shares of the company’s stock, valued at approximately $41,529,602.82. This trade represents a 30.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 184,592 shares of company stock valued at $24,499,532 in the last three months. 8.20% of the stock is owned by insiders.

Institutional Trading of Revolution Medicines

A number of institutional investors and hedge funds have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its stake in Revolution Medicines by 197.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,205,555 shares of the company’s stock worth $175,672,000 after acquiring an additional 1,463,155 shares in the last quarter. Nextech Invest Ltd. boosted its stake in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Revolution Medicines in the 2nd quarter worth about $44,148,000. Bellevue Group AG grew its holdings in shares of Revolution Medicines by 21.7% in the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after purchasing an additional 994,538 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its position in shares of Revolution Medicines by 200.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $95,580,000 after purchasing an additional 800,000 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: NEJM publication and Phase?3 momentum — Phase 1/2 daraxonrasib data were published in the New England Journal of Medicine, reinforcing the scientific rationale for RASolute 302 (the pivotal Phase 3 pancreatic cancer trial) and supporting planned regulatory submissions. NEJM Publication on Daraxonrasib
• Positive Sentiment: Phase?3 readout and regulatory path — Company announced RASolute 302 showed an “unprecedented” survival benefit and plans to present data at ASCO and submit to global regulators, a development that materially de?risks a potential commercial pathway if regulators agree. Q1 Results and RASolute 302 Update
• Positive Sentiment: Analyst bullishness — Several firms raised targets/ratings (Piper Sandler to $172 overweight; Wedbush and RBC to $165/outperform), signaling increased sell?side confidence in the commercial opportunity and valuation upside. Piper Sandler Price Target Raise
• Positive Sentiment: Balance-sheet cushion — Company reported financings totaling ~$2.2 billion in gross proceeds, improving runway for late?stage development and commercial preparation. Financial Results and Financing
• Neutral Sentiment: Safety profile context — Reuters notes daraxonrasib produced a high rate of mostly low?grade side effects; these are manageable but could affect labeling, uptake, and commercial messaging. Reuters on Daraxonrasib Side Effects
• Negative Sentiment: Q1 miss and higher expense guide — RVMD reported a wider-than-expected Q1 loss (EPS -$2.29 vs. consensus -$1.83) and raised its 2026 expense outlook as R&D and commercial prep costs climb; near-term profitability metrics will remain weak. Zacks Q1 Loss and Expense Outlook
• Negative Sentiment: Warrant expiry/dilution risk — Analysts flag warrants expiring in 2026 that could either dilute shareholders if exercised or become worthless; this adds execution and capital?structure uncertainty ahead of key milestones. TipRanks on Warrants and Dilution

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.